PTC Therapeutics reported $536.27M in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
Amgen USD 51.61B 250M Sep/2026
BioCryst Pharmaceuticals USD 395.61M 209K Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Cytokinetics USD 244.33M 3.87M Sep/2026
Daiichi Sankyo JPY 499.93B 75M Sep/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 23.82B 17M Sep/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Novartis USD 38.38B 893M Sep/2026
Pfizer USD 60B 498M Sep/2026
PTC Therapeutics USD 536.27M 749K Sep/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
TG Therapeutics USD 745.63M 247K Sep/2026
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026
Xencor USD 71.93M 5.61M Sep/2026